JPMorgan Chase & Co. reduced its position in shares of Radius Health, Inc. (NASDAQ:RDUS) by 32.8% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 120,554 shares of the biopharmaceutical company’s stock after selling 58,780 shares during the quarter. JPMorgan Chase & Co. owned 0.28% of Radius Health worth $5,452,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in RDUS. Ameritas Investment Partners Inc. bought a new stake in Radius Health during the 1st quarter valued at about $105,000. Sei Investments Co. increased its stake in Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 690 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Radius Health by 1.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after purchasing an additional 46 shares in the last quarter. Blair William & Co. IL bought a new stake in Radius Health during the 2nd quarter valued at about $205,000. Finally, Karp Capital Management Corp bought a new stake in Radius Health during the 1st quarter valued at about $217,000.

A number of analysts have weighed in on the stock. BidaskClub upgraded shares of Radius Health from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. ValuEngine upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $65.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research note on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $53.60.

Shares of Radius Health, Inc. (RDUS) opened at 38.48 on Friday. The company’s market capitalization is $1.67 billion. Radius Health, Inc. has a 52 week low of $31.58 and a 52 week high of $55.97. The stock has a 50 day moving average of $36.49 and a 200-day moving average of $38.70.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.23). The company had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.96 million. During the same period in the prior year, the firm earned ($1.01) earnings per share. On average, analysts anticipate that Radius Health, Inc. will post ($5.58) EPS for the current year.

In related news, CFO Jose Carmona acquired 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was purchased at an average cost of $32.83 per share, with a total value of $98,490.00. Following the transaction, the chief financial officer now directly owns 3,000 shares of the company’s stock, valued at approximately $98,490. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Growth N. V. Biotech acquired 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average cost of $34.97 per share, with a total value of $5,245,500.00. Following the completion of the transaction, the insider now directly owns 5,113,799 shares in the company, valued at $178,829,551.03. The disclosure for this purchase can be found here. Insiders purchased a total of 469,100 shares of company stock valued at $16,328,382 over the last ninety days. 15.00% of the stock is currently owned by insiders.

WARNING: “JPMorgan Chase & Co. Has $5.45 Million Holdings in Radius Health, Inc. (RDUS)” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/jpmorgan-chase-co-has-5-45-million-holdings-in-radius-health-inc-rdus/1611792.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.